Sodium Oligomannate: First Approval
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sodium oligomannate ( ® ; GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer's disease (AD). Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function. This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“New drugs, including sodium oligomannate (9, GV-971),54–56 aducanumab (1),57–59 lecanemab (2),60–62 and donanemab (10, currently under review for market approval),63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [54]
In the citing paper
“Sodium oligomannate (9, GV-971), an oligosaccharide extracted from marine algae, was conditionally approved in China in 2019 amidst ongoing debates regarding its mechanism of action and therapeutic efficacy.54,413”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [54]
Citations
Cites
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965 · cited 2×
“Alzheimer’s disease (AD) pathology is characterized by the aggregation of amyloid β-peptide (Aβ) in extracellular senile plaques and hyperphosphorylated tau protein in intracellular neurofibrillary tangles in the brain [1, 2].”
BackgroundDrug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
The microbiome: A target for Alzheimer disease?
Seo, D.-O., Boros, B. D., & Holtzman, D. M. (2019) · Cell Research · doi:10.1038/s41422-019-0227-7 · Cited by 56
Synthesis and bioassay of β-(1,4)-D-mannans as potential agents against Alzheimer's disease
Jiang, R.-W., Du, X.-G., Zhang, X., Wang, X., Hu, D.-Y., Meng, T., Chen, Y.-L., Geng, M.-Y., & Shen, J.-K. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.104 · Cited by 37 · cited 1×
“Sodium oligomannate exhibited a neuroprotective effect against Aβ toxicity in human neuroblastoma cells [12] and showed favourable effects in rodent models of Aβ, d-galactose-induced memory impairment or scopolamine-induced memory impairment [8].”
BackgroundMarine glycan-derived therapeutics in China
Gao, Y., Zhang, L., & Jiao, W. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.02.006 · Cited by 23 · cited 1×
“Sodium oligomannate is produced by depolymerizing alginate and subsequent oxidation to oligosaccharides [11].”
Background(2019) · Science · doi:10.1126/science.366.6466.668 · Cited by 3
Research works printed but not linked: 2
- Xiao S. A phase II clinical trial on GV-971 in patients with Alzheimer’s [abstract no. OC 3]. J Prev Alz Dis. 2014;1(3):214–96.
- Shi-fu X. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer disease [abstract]. Chin J Pharmacol Toxicol. 2019;6(6):403.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“544,553 The respective optimized derivatives of BQCA ( 53 ) and PF06764427 ( 54 ), compounds 55 .”
BackgroundAlzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
“Sodium oligomannate (GV-971), a derivative of marine algae oligosaccharides, received conditional approval in China to treat mild to moderate AD in 2019 [260].”
BackgroundPathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
“In November 2019, China approved the use of sodium oligo-mannate for the treatment of mild to moderate AD (Syed, 2020).”
BackgroundThe complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 309
Metadata
- Authors
- Syed, Y. Y.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Syed, Yahiya Y.
- ORCID
- Syed, Yahiya Y.
- Venue
- Drugs
- Published
- 2020-02-04
- Volume
- 80
- Issue
- 4
- Pages
- 441-444
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3005220370
- Cited by
- 187
- References
- 7
- Citations by year
- 2026: 23 · 2025: 29 · 2024: 33 · 2023: 32 · 2022: 38 · 2021: 15 · 2020: 17
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-02-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug approval, cognitive function, drug development milestones
- MeSH terms
- Alzheimer Disease, Animals, China, Humans, Mannose, Oligosaccharides, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium Oligomannate: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01268-1
- The paper
- Syed, Y. Y. (2020). Sodium Oligomannate: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01268-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.